<?xml version="1.0" encoding="UTF-8"?>
<p>Liquid elderberry extract is characterized by antiviral action in vitro against influenza, as well as respiratory bacterial pathogens [
 <xref rid="B22-pharmaceuticals-13-00313" ref-type="bibr">22</xref>,
 <xref rid="B55-pharmaceuticals-13-00313" ref-type="bibr">55</xref>]. There is preclinical evidence that elderberry (
 <italic>Sambucus nigra</italic> L. (
 <italic>Adoxaceae</italic>)) inhibits the replication and viral attachment of the human coronavirus NL63 (HCoV-NL63) [
 <xref rid="B56-pharmaceuticals-13-00313" ref-type="bibr">56</xref>], which differs from COVID-19 but also belongs to coronaviruses. Elderberry is the most effective means of preventing or combating coronavirus infections at an early stage [
 <xref rid="B57-pharmaceuticals-13-00313" ref-type="bibr">57</xref>]. The authors of [
 <xref rid="B58-pharmaceuticals-13-00313" ref-type="bibr">58</xref>] provide evidence of the effectiveness of elderberry use against influenza, which can be useful in determining COVID-19 preventive tactics (the authors provide daily recommendations for a typical daily dosage of elderberry extract for adults and children).
</p>
